Halozyme Therapeutics Inc. Stock
The Halozyme Therapeutics Inc. stock is trending slightly upwards today, with an increase of €0.22 (0.520%) compared to yesterday's price.
With 14 Buy predictions and not the single Sell prediction the community is currently very high on Halozyme Therapeutics Inc..
With a target price of 50 € there is a slightly positive potential of 19.73% for Halozyme Therapeutics Inc. compared to the current price of 41.76 €.
Pros and Cons of Halozyme Therapeutics Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
M***** P*******
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Halozyme Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc. | 0.520% | 6.858% | 14.631% | 36.204% | 23.368% | 18.704% | - |
| Ironwood Pharmaceuticals | -1.650% | -20.667% | -18.493% | -38.021% | -41.667% | -37.696% | - |
| Sage Therapeutics Inc. | 3.160% | -4.250% | -25.025% | -76.709% | -44.800% | -81.955% | - |
| Novocure Ltd | 5.170% | 35.076% | 74.072% | -72.501% | 42.977% | -86.172% | - |
Comments
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $50.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat
Halozyme Therapeutics, Inc. (NASDAQ: HALO) had its "buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $50.00 price target on the stock.
Show more
Ratings data for HALO provided by MarketBeat